RxDoctor Payments Data

Stephen Mitchell, MD

Rheumatology · Washington, DCNPI 1194713503

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,648,530 of the $1,648,581 with a category attached, or 100.0%. Vanda Pharmaceuticals Inc. accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Among rheumatology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,648,581in general payments, 2019–2025

Across 35 payments — averaging $47,102 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$1.6M
  • Covidien LP$51

What the payments were for

  • Speaking & faculty fees$1,648,530100%
  • Food & beverage$510%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vanda Pharmaceuticals Inc.33$1,648,530
Covidien LP2$51

How this compares

$1,648,581 in reported general payments places this provider in the 95th percentile of 41 rheumatology providers in District of Columbia.

See all rheumatology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$11,648
Medicare patients
31
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab14$97,713
Enbrel SureclickEtanercept12$87,195
HumiraAdalimumab12$82,237
MethotrexateMethotrexate Sodium28$911
Prednisone13$154

Paid to pharmacies, not to this prescriber.

Other rheumatology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →